Restorgenex Corporation (RESX) 1.5000 $RESX Diffusion

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Restorgenex Corporation (RESX) 1.5000 $RESX

Diffusion Pharmaceuticals Announces Stock Ticker Symbol Change to DFFN
GlobeNewswire - Mon Jan 25, 6:30AM CST
Diffusion Pharmaceuticals Inc., a clinical stage biotechnology company focused on the development of novel small molecule therapeutics for cancer, today announced that FINRA has approved a change in the Company's stock symbol. Effective today, the Company's common shares will commence trading on the OTC Markets under the trading symbol "DFFN" (OTCQXFFN). The previous trading symbol was "RESX" (OTCQX:RESX).

Diffusion Pharmaceuticals Announces Presentation at Biotech Showcase 2016
GlobeNewswire - Fri Jan 08, 3:08PM CST
Diffusion Pharmaceuticals, LLC (OTCQX:RESX), a clinical stage biotechnology company focused on the development of novel small molecule therapeutics for cancer, today announced that management will be presenting at Biotech Showcase 2016 to be held January 11 - 13, 2016 in San Francisco.

Diffusion Pharmaceuticals Completes Merger With RestorGenex and Becomes a Publicly Traded Oncology-Focused Biotechnology Company
GlobeNewswire - Fri Jan 08, 3:05PM CST
Diffusion Pharmaceuticals LLC, a clinical-stage biotechnology company focused on the development of novel small molecule therapeutics for cancer, today announced the successful completion of its merger with RestorGenex Corporation (OTCQX:RESX). The combined company is changing its name to Diffusion Pharmaceuticals Inc.

The Life Sciences Report Announces the RestorGenex and Diffusion Pharmaceuticals Merger
Marketwired - Mon Dec 28, 8:00AM CST
The merger of RestorGenex Corp. (OTCQX: RESX) and privately held Diffusion Pharmaceuticals LLC, announced Tuesday, Dec. 15, will create an oncology-focused clinical-stage company with a diversified development portfolio of product candidates addressing novel targets, including several orphan indications, according to a press release issued by the companies. The combined company will be named Diffusion Pharmaceuticals Inc. and will be headquartered in Charlottesville, Virginia.

Maxim Group's Jason Kolbert and Jason McCarthy Interviewed by The Life Sciences Report
Marketwired - Fri Dec 04, 8:00AM CST
Why have stem cell and regenerative medicine companies underperformed other segments of biotech? Maxim Group's Jason Kolbert and Dr. Jason McCarthy identify a possible answer: Investors believe stem cell data has yet to definitively reach proof of concept in the blockbuster indications that the companies are pursuing. They want to see results like those shown by gene therapy/CAR-T companies, such as bluebird bio Inc. ("the Bird" in sickle cell disease. In this interview with The Life Sciences Report, Kolbert and McCarthy tackle the issues that have frustrated investors, and leave readers with a list of names that could reap multiples on investment while patients enjoy longer lives.
ATHX: 1.95 (-0.01), IMUC: 0.13 (unch), BCLI: 2.37 (+0.02)

RestorGenex Reports Third Quarter 2015 Financial Results
GlobeNewswire - Thu Nov 12, 3:15PM CST
RestorGenex Corporation (OTCQX:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today reported on its cash balance and financial results for the nine months ended September 30, 2015.

SeeThruEquity's Ajay Tandon and Jay Albany Interviewed by The Life Sciences Report
Marketwired - Thu Oct 29, 12:17PM CDT
SeeThruEquity's Ajay Tandon and Jay Albany are riding the biotech bull by harnessing the huge upside potential of micro-cap companies working in multiple subsectors, particularly in the rapidly advancing cancer immunotherapy sector. In this interview with The Life Sciences Report, Tandon and Albany toss the names of several companies into the arena for investors' consideration.
AEMD: 6.45 (-1.25)

RestorGenex to Present at Two Upcoming Growth Conferences
GlobeNewswire - Tue Oct 06, 6:00AM CDT
RestorGenex Corporation (OTCQX:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, RestorGenex's CEO, will provide a company overview at two upcoming growth conferences featuring biotechnology and pharmaceutical companies.

RestorGenex to Present at Rodman & Renshaw Global Investment Conference
GlobeNewswire - Thu Sep 03, 5:29AM CDT
RestorGenex Corporation (OTCQX:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, RestorGenex's CEO, will present a corporate overview at the Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co. The conference will be held September 8-10, 2015 at the St. Regis Hotel in New York City.

RestorGenex Reports Financial Results
GlobeNewswire - Wed Aug 12, 5:30AM CDT
RestorGenex Corporation (OTCQX:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today reported its cash balance and financial results for the six months ended June 30, 2015.

RestorGenex Announces Positive 3-D Cancer Cell Culture Data for RES-529, a TORC1/TORC2 Inhibitor
GlobeNewswire - Tue Jul 14, 5:30AM CDT
RestorGenex Corporation (OTCQX:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced positive data from a 3-D Cancer Cell Proliferation Assay with RES-529 and three analogs. The assay confirmed RES-529 activity for the lead indication of glioblastoma, while also demonstrating activity in several other oncology cell lines.

SeeThruEquity Initiates Coverage on RestorGenex Corp. with a Price Target of $8.93
ACCESSWIRE - Wed Jul 08, 8:02AM CDT
NEW YORK, NY / ACCESSWIRE / July 8, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage of RestorGenex Corp. (OTCQX: RESX) with a price target of $8.93.

OTC Markets Group Welcomes RestorGenex to OTCQX
PR Newswire - Wed Jul 08, 6:00AM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced RestorGenex Corporation (OTCQX: RESX), a specialty biopharmaceutical company, has qualified to trade on the OTCQX® Best Marketplace.

RestorGenex Announces Presentation of Prostate Cancer Data on RES-529, a Dual TORC1/TORC2 Inhibitor
GlobeNewswire - Fri Jun 19, 5:30AM CDT
RestorGenex Corporation (OTC:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that in vitro and in vivo data will be presented on the use of RES-529 in a prostate cancer cell model. The data titled, "RES-529, A Dual TORC1/TORC2 Inhibitor, Potentiates the In Vitro and In Vivo Efficacy of Hormone Manipulations in the 22RV1 Prostate Cancer Cell Model" will be presented by Claudio Festuccia, Department of Clinical Sciences and Applied Biotechnology, Universita degli Studi dell'Aquila, at the XXVth National Congress of the Italian Society of Uro-Oncology (SIUrO), on June 22, 2015 in Rome, Italy.

RestorGenex Announces Stockholder Approval of Reincorporation in Delaware
GlobeNewswire - Thu Jun 18, 5:30AM CDT
RestorGenex Corporation (OTC:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, announced today that stockholders in an annual meeting yesterday voted to reincorporate the company in Delaware effective promptly upon regulatory filings in Delaware and Nevada. The company intends to make these regulatory filings today, June 18, 2015. The company's common stock will continue to trade under the symbol "RESX".

RestorGenex CEO Featured in Equities.com Interview
GlobeNewswire - Tue Jun 16, 5:30AM CDT
RestorGenex Corporation (OTC:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, chief executive officer of RestorGenex, was interviewed by Ed Kershen of Equities.com.

Restorgenex Corporation (RESX) to Present at the Small-Cap Stars Spring Conference 2015 at Convene in Times Square New York on June 10
GlobeNewswire - Thu Jun 04, 7:02AM CDT
Restorgenex Corporation (OTCMKTS:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, will be presenting at the Small-Cap Stars Spring Conference 2015 at Convene in Times Square New York on Wednesday, June 10. The event is a gathering of the brightest emerging growth small-cap and pre-IPO companies to present and network with an exclusive group of top-level institutional investors.

RestorGenex to Present at the Annual LD Micro Invitational Conference
GlobeNewswire - Mon Jun 01, 5:30AM CDT
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, chief executive officer of RestorGenex, is scheduled to present a corporate overview at the 5 Annual LD Micro Invitational Conference in Los Angeles, CA, on Tuesday, June 2, 2015 at 4:30 pm PT.

RestorGenex Announces Data on the Effect of RES-529 in Pulmonary Fibrosis Models
GlobeNewswire - Thu May 21, 5:00AM CDT
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, announced that Keith Ferguson, M.D. and Nathan Sandbo, M.D., both of the Division of Allergy, Pulmonary, and Critical Care Medicine, University of Wisconsin School of Medicine and Public Health, presented scientific data utilizing RES-529 in idiopathic pulmonary fibrosis. The poster entitled "The Novel TOR Complex 1/2 Inhibitor RestorGenex 529 (RES-529) Inhibits Human Lung Myofibroblast Differentiation" was presented on Tuesday, May 19, 2015 at the American Thoracic Society International Conference in Denver, Colorado.

RestorGenex to Present at Two Investor Conferences
GlobeNewswire - Wed May 20, 3:00PM CDT
RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that Stephen M. Simes, chief executive officer of RestorGenex, is scheduled to present a corporate overview at two upcoming investor conferences.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 8

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 371

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 283

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 334

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 442

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 247

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 278

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 460

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 522

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 438

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading

Top 5 Most Recently Viewed Articles

JOYY Inc.'s Solid Growth: Third Quarter Financial Breakdown

Updated Category News Views 318

JOYY Inc. Reports Strong Financial Performance for Q3 2025 JOYY Inc. (NASDAQ: JOYY), a leading global technology enterprise, released its unaudited financial results for the third quarter of 2025, showcasing promising growth figures and strategic advancements across its various business segments. Financial Highlights for Q3 2025 In the third quarter, JOYY achieved net...

Continue Reading
Celebrating Innovation: FAST TRACK GROUP and Dongfeng EV Launch

Updated Category News Views 152

FAST TRACK GROUP and Dongfeng’s Electric Vehicle Launch FAST TRACK GROUP (NASDAQ: FTRK) has successfully completed a dynamic brand activation project for the electric vehicle (EV) brand Dongfeng Singapore. This exciting partnership highlights the group's expertise in event management and celebrity engagement, set against the backdrop of a rapidly evolving automotive...

Continue Reading
Cerulean Ventures Secures $10M Fund to Tackle Climate Challenges

Updated Category News Views 101

Cerulean Ventures Secures $10M Pre-Seed Fund Cerulean Ventures, a prominent venture capital firm focused on climate technology, recently achieved a significant milestone by closing a $10 million pre-seed fund. This fund is specifically aimed at supporting innovative software solutions designed to tackle urgent climate challenges. It emphasizes scalable software...

Continue Reading
OPEC+ Production Increase: Impact on Oil Prices and Markets

Updated Category News Views 461

OPEC+ was reportedly considering a significant bump in oil production back in late 2024, which flipped the script from their previous strategy of holding steady. Traders were already reacting as analysts suggested this shift could disrupt supply-demand dynamics in an already volatile market. Saudi Arabia's Strategy: Price Cuts for Market Share As the heavyweight champion...

Continue Reading
Norway's Prime Minister Expresses Concerns Over Musk's Influence

Updated Category News Views 155

Norway's Prime Minister Raises Alarm Over Elon Musk's Involvement OSLO - Norway's Prime Minister, Jonas Gahr Stoere, has recently voiced his apprehensions regarding the significant influence of Elon Musk in political matters beyond the borders of the United States. His remarks were made during an interview with the Norwegian public broadcaster NRK, where he expressed...

Continue Reading